DHEA and SERM Combination Therapy for Menopausal Symptom Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hormonal therapies for menopausal symptoms and cancer risk management are limited by side effects such as breast cancer exacerbation, endometrial cancer risk, and undesirable masculinizing effects, and fail to effectively address hot flushes, vasomotor symptoms, and osteoporosis.
Innovation Solution
Administration of a precursor of sex steroids, such as dehydroepiandrosterone (DHEA), in combination with a selective estrogen receptor modulator (SERM) to reduce the incidence of hot flushes, vasomotor symptoms, and cancer risks while minimizing side effects by local formation of androgens and estrogens in peripheral tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If conventional hormonal therapies (estrogens, androgens, progestins) are administered to treat menopausal symptoms and prevent osteoporosis, then bone density is improved and menopausal symptoms are reduced, but the risk of breast cancer, endometrial cancer, and masculinizing side effects increases
Solution Approach 1:
The patent uses dehydroepiandrosterone (DHEA) as an intermediary substance that is converted locally in peripheral tissues into androgens and estrogens. This indirect approach allows hormonal activity at the tissue level without exposing the breast and endometrium to systemic hormonal stimulation, thereby maintaining bone density while reducing cancer risk
Solution Approach 2:
The invention exploits the local conversion of DHEA into active sex steroids in peripheral tissues such as bone and brain. This creates localized hormonal effects where needed (for bone density and cognitive function) while avoiding systemic exposure that would stimulate breast and endometrial tissue, thus resolving the contradiction between therapeutic benefit and cancer risk
2Ease of operation
If estrogens are administered to reduce hot flushes and vasomotor symptoms, then symptom relief is achieved, but breast cancer risk is exacerbated
Solution Approach 1:
DHEA serves as a precursor that is converted locally into estrogens in target tissues like the brain and bone, providing symptom relief without direct systemic estrogen administration. This intermediary approach delivers estrogenic effects where needed while minimizing stimulation of breast tissue
Solution Approach 2:
The patent changes the parameter of hormone administration from direct estrogen to its precursor DHEA. This transformation allows the body to produce estrogen locally in a controlled manner, providing therapeutic benefits for hot flushes while the accompanying SERM counteracts potential breast cancer risk
3Strength
If androgenic compounds are administered to treat menopausal symptoms, then bone mass is built and symptoms are reduced, but masculinizing side effects occur
Solution Approach 1:
DHEA acts as an intermediary that is converted locally into androgens in bone tissue and other peripheral tissues. This local conversion provides the bone-building effects of androgens while avoiding high systemic levels that would cause masculinizing side effects
Solution Approach 2:
The invention creates local androgen production in specific tissues (bone, brain) through DHEA conversion, providing tissue-specific benefits without systemic androgen exposure. This resolves the contradiction by concentrating androgenic effects where needed while minimizing unwanted side effects
Data Source
AI summary
Novel methods for reduction or elimination the incidence of hot flushes, vasomotor symptoms, and night sweats while decreasing the risk of acquiring breast, uterine or endometrial cancer and furthermore having beneficial effect by inhibiting the development of osteoporosis, hypercholesterolemia, hyperlipidemia, atherosclerosis, hypertension, insulin resistance, diabetes type 2, loss of muscle mass, adiposity, Alzheimer's disease, loss of cognition, loss of memory, or vaginal dryness in susceptible warm-blooded animals including humans involving administration of an amount of a sex steroid precursor, particularly dehydroepiandrosterone (DHEA) and an antiestrogen or a selective estrogen receptor modulator, particularly compounds having the general structure:Pharmaceutical compositions for delivery of active ingredient(s) and kit(s) useful to the invention are also disclosed.